TMCI TREACE MEDICAL CONCEPTS, INC.
FY2025 10-K
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed its fiscal year 2025 10-K annual report with the SEC on Feb 27, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Development, marketing, and sales of bunion correction surgical systems and instruments in the U.S., primarily via direct sales force and distributors
- • New products emphasized: Minimally invasive osteotomy systems (Nanoplasty, Percuplasty), great toe fusion system, and next-gen Lapiplasty Lightning Instrumentation expected in 2026
Management Discussion & Analysis
- • Revenue $212.7M in 2025, up 1.6% YoY from $209.4M in 2024
- • Net loss increased to $59.0M in 2025 from $55.7M in 2024; operating margin negative approx. -25.5% in 2025 vs -26.6% in 2024 (loss from operations $54.2M vs $55.7M)
Financial SummaryXBRL
Revenue
$213M
Net Income
-$59M
Gross Margin
79.8%
Operating Margin
-25.5%
Net Margin
-27.7%
ROE
-67.6%
Total Assets
$191M
EPS (Diluted)
$-0.93
Operating Cash Flow
-$16M
Source: XBRL data from TREACE MEDICAL CONCEPTS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on TREACE MEDICAL CONCEPTS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.